摘要
目的探讨炎性细胞比值对乳腺癌新辅助化疗疗效和疾病进展风险预测的价值。方法回顾性分析2016年1月—2020年5月收治的105例行新辅助化疗的乳腺癌患者的临床资料,根据新辅助化疗疗效分为pCR组27例和未pCR组78例,对比2组临床资料和实验室指标;根据2年内疾病进展情况将患者分为进展组22例和未进展组83例,比较2组患者实验室指标,分析不同炎性细胞比值患者的无进展生存期。结果pCR组患者年龄、Her2阳性比例、LYM、LMR高于未pCR组(P<0.05),NEU、NLR、PLR低于未pCR组(P<0.05);年龄、Her2状态、NLR、LMR、PLR是影响乳腺癌新辅助化疗疗效的主要因素(P<0.05);NLR、LMR、PLR预测乳腺癌新辅助化疗疗效的AUC分别为0.814、0.683、0.770;进展组患者NLR高于无进展组(P<0.05),LMR低于无进展组(P<0.05);高NLR组患者PFS短于低NLR组(P<0.05),高LMR组患者PFS长于低LMR组(P<0.05)。结论NLR、LYM、PLR在预测乳腺癌新辅助化疗疗效方面有一定价值,且NLR、LYM可作为疾病进展风险预测的辅助参考指标。
Objective This paper aims to investigate the value of inflammatory cell ratio in predicting the efficacy of neoadjuvant chemotherapy and the risk of disease progression in breast cancer.Methods Clinical data of 105 breast cancer patients receiving neoadjuvant chemotherapy from January 2016 to May 2020 were retrospectively analyzed.According to the efficacy of neoadjuvant chemotherapy,they were divided into the pCR group(n=27)and the non-pCR group(n=78).Clinical data and laboratory indicators of the two groups were compared.According to the disease progression within 2 years,the patients were divided into a progressive group(22 cases)and a non-progressive group(83 cases).The laboratory indicators of the two groups were compared to analyze the progression-free survival of patients with different inflammatory cell ratios.Results Age,Her2 positive ratio,LYM and LMR in pCR group were significantly higher than those in non-pCR group(P<0.05),and NEU,NLR and PLR were significantly lower than those in non-pCR group(P<0.05).Age,Her2 status,NLR,LMR and PLR were the main factors affecting the efficacy of neoadjuvant chemotherapy(P<0.05).The AUC of NLR,LMR and PLR in predicting the efficacy of neoadjuvant chemotherapy for breast cancer were 0.814,0.683 and 0.770,respectively.NLR in the progressive group was higher than that in the non-progressive group(P<0.05),and LMR was lower than that in progression-free group(P<0.05).PFS in the high level NLR group was shorter than that in the low level NLR group(P<0.05),and PFS in high level LMR group was longer than that in low level LMR group(P<0.05).Conclusion NLR,LYM and PLR have a certain value in predicting the efficacy of neoadjuvant chemotherapy for breast cancer,and NLR and LYM can be used as auxiliary reference indicators for predicting the risk of disease progression.
作者
刘翔
杜璐迪
舒敬德
LIU Xiang;DU Lu-di;SHU Jing-de(Breast Thyroid Surgery,Quzhou Hospital Affiliated to Wenzhou Medical University(Quzhou People's Hospital),Zhejiang 324000,China)
出处
《中国卫生检验杂志》
CAS
2023年第6期703-707,共5页
Chinese Journal of Health Laboratory Technology
基金
衢州市科技攻关项目(2021Y007)。
关键词
乳腺癌
新辅助化疗
炎性细胞
疾病进展
淋巴细胞
中性粒细胞
Breast cancer
Neoadjuvant chemotherapy
Inflammatory cells
Disease progression
Lymphocyte
Neutrophils
